- Report
- February 2021
- 360 Pages
United States
From €2305EUR$2,400USD£1,985GBP
- Report
- February 2019
- 105 Pages
Global
From €1239EUR$1,290USD£1,067GBP
- Drug Pipelines
- June 2019
- 579 Pages
Global
€21130EUR$22,000USD£18,192GBP
- Report
- June 2019
- 16 Pages
Global
€9605EUR$10,000USD£8,269GBP
- Report
- June 2019
- 21 Pages
Global
€9605EUR$10,000USD£8,269GBP
- Report
- June 2019
- 18 Pages
Global
€9605EUR$10,000USD£8,269GBP
- Report
- January 2019
- 717 Pages
Global
From €21130EUR$22,000USD£18,192GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €480EUR$500USD£413GBP
- Report
- January 2019
- 35 Pages
Global
From €960EUR$1,000USD£827GBP
- Report
- June 2019
- 26 Pages
Global
€9605EUR$10,000USD£8,269GBP
Prezista is a medication used to treat HIV and hepatitis C infections. It is a protease inhibitor, meaning it works by blocking the action of a specific enzyme that is needed for the virus to replicate. Prezista is used in combination with other antiretroviral drugs to treat HIV infection and is also used to treat chronic hepatitis C infection. It is typically prescribed to patients who have not responded to other treatments or who have developed resistance to other medications.
Prezista is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Other companies in the market include Gilead Sciences, AbbVie, Bristol-Myers Squibb, and Merck & Co. Show Less Read more
